- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02727075
Performance Value of Research of Occult Gastrointestinal Bleeding by Immunoassay in the Diagnostic Process of Iron Deficiency Anemia in Patients Over 75 Years (STRATAGANEMIE)
This study aims to characterize the diagnostic performance of immunological testing of occult gastrointestinal bleeding in stool in the population aged over 75 years with iron deficiency anemia.
As secondary objectives, the study aims to:
- determine a threshold of positivity optimizing the immunoassay performance for the study population, in accordance with the probabilities of error (false positives, false negatives) and weights (defined by expert consensus) allocated to these errors.
- Assess the benefit of a double measure of bleeding (two stools) by immunoassay compared to a single measure.
Study Overview
Status
Conditions
Detailed Description
Immunological testing will be performed systematically for each patient.
Research of blood in fecal sample will be based on 2 methods: one based on a qualitative immunochromatographic method (such as HemSign4 technique, Servibio, France; or all other techniques used at AP-HP) and another quantitative immunoturbidimetric method (OC-Sensor, Eiken, Japan). They will be performed systematically with two fresh fecal samples for each patient, before coloscopy examination.
Treating physicians will not be provided with the testing result. The diagnosis of reference will be established by experts based on the result of explorations (colonoscopy, coloscanner) and the patient's progression, blinded to the result of immunoassay.
The intrinsic characteristics of the immunoassay (sensitivity, specificity...) will be determined with reference to this reference diagnosis, using a positivity threshold defined using expert consensus on the weights to be allocated to potential errors.
2 modeling scenarios (without vs with immunological testing) using decision trees based on prevalence and diagnostic performance observed and stochastic simulations.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Hauts-de-Seine
-
Boulogne-Billancourt, Hauts-de-Seine, France, 92100
- Service Hépato-Gastroentérologie, Hôpital Ambroise Paré
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Physical status score 3 or 4, aged 75 and older patient, (patients under guardianship may be included).
- Iron deficiency anemia (Hb≤120 g/l for a woman or Hb≤130 g/l for a man), and nonregenerative anemia with reticulocytes <120 000/mm3.
- Patient who has indication for colonoscopy and / or colonography examination, whatever the results of gastroscopy if performed.
- Have a health insurance.
- Informed consent signed.
Exclusion Criteria:
- Hematemesis or melena
- Life expectancy inferior to 12 months
- Patient has difficulty in follow-up of study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity of immunological test with OC-SENSOR supplies
Time Frame: At baseline
|
The immunological test with OC-SENSOR supplies is a quantitative determination of hemoglobin, the method of detection of lower gastrointestinal hemorrhagic lesions of older population with iron deficiency anemia. Sensitivity of the immunological test will be calculated statistically. |
At baseline
|
Specificity of immunological test with OC-SENSOR supplies
Time Frame: At baseline
|
The immunological test with OC-SENSOR supplies is a quantitative determination of hemoglobin, the method of detection of lower gastrointestinal hemorrhagic lesions of older population with iron deficiency anemia. Specificity of the immunological test will be calculated statistically. |
At baseline
|
Likelihood ratios of immunological test with OC-SENSOR supplies
Time Frame: At baseline
|
The immunological test with OC-SENSOR supplies is a quantitative determination of hemoglobin, the method of detection of lower gastrointestinal hemorrhagic lesions of older population with iron deficiency anemia. Likelihood rations of the immunological test will be calculated statistically. |
At baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic Performance
Time Frame: At baseline
|
Diagnostic Performance of predictive equation incorporating all individual data will be calculated statistically.
|
At baseline
|
Comparing scenarios using decision trees
Time Frame: At baseline
|
Compare using modeling (decision trees) the causal efficiency (number of origins of bleeding detected / number of coloscopy-colonoscopy performed) of two scenarios: without (base case) and with the immunoassay to research occult bleeding in feaces (with one or two fecal samples).
|
At baseline
|
Performance of the test when used with an optimized positivity threshold
Time Frame: At baseline
|
Sensitivity, specificity and likelihood ratios of the immunological testing will be calculated statistically, when an optimized positivity threshold for the population under study is used, as a function of weights (defined by experts consensus) allocated to errors (false negative and false positive cases).
|
At baseline
|
Collaborators and Investigators
Investigators
- Study Director: Dominique Lamarque, MD, PhD, Service Hépato-Gastroentérologie, Hôpital Ambroise Paré
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P140307
- AOR14082 (OTHER: Department of Clinical Research & Development - APHP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Occult Gastrointestinal Bleeding
-
Assistance Publique - Hôpitaux de ParisCompletedOccult Gastrointestinal BleedingFrance
-
University of Southern CaliforniaCompletedObscure Gastrointestinal Bleeding (Occult or Overt)United States
-
US Department of Veterans AffairsTerminatedOccult GI BleedingUnited States
-
Norman A. ParadisUnited States Department of Defense; Dartmouth College; University of Maryland...Not yet recruitingHemorrhage | Occult BleedingUnited States
-
Dartmouth-Hitchcock Medical CenterUnited States Department of Defense; Ohio State University; Dartmouth CollegeTerminatedHemorrhage | Hemorrhagic Shock | Occult BleedingUnited States
-
University of TabukMinistry of Health, Saudi Arabia; Ein Al-Hayat Medical Complex; The Charitable... and other collaboratorsCompletedColorectal Neoplasms | Colorectal Cancer | Colonic Polyp | Occult BleedingSaudi Arabia
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
National University of SingaporeRecruitingGastroIntestinal BleedingSingapore